{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:26:47Z","timestamp":1790735207323,"version":"4.1.0"},"reference-count":198,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIAAA-NIH grant AA027909"],"award-info":[{"award-number":["NIAAA-NIH grant AA027909"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The endocannabinoid system (ECS) is ubiquitous in most human tissues, and involved in the regulation of mental health. Consequently, its dysregulation is associated with neuropsychiatric and neurodegenerative disorders. Together, the ECS and the expanded endocannabinoidome (eCBome) are composed of genes coding for CB1 and CB2 cannabinoid receptors (CB1R, CB2R), endocannabinoids (eCBs), and the metabolic enzyme machinery for their synthesis and catabolism. The activation of CB1R is associated with adverse effects on the central nervous system (CNS), which has limited the therapeutic use of drugs that bind this receptor. The discovery of the functional neuronal CB2R raised new possibilities for the potential and safe targeting of the ECS for the treatment of CNS disorders. Previous studies were not able to detect CB2R mRNA transcripts in brain tissue and suggested that CB2Rs were absent in the brain and were considered peripheral receptors. Studies done on the role of CB2Rs as a potential therapeutic target for treating different disorders revealed the important putative role of CB2Rs in certain CNS disorders, which requires further clinical validation. This review addresses recent advances on the role of CB2Rs in neuropsychiatric and neurodegenerative disorders, including, but not limited to, anxiety, depression, schizophrenia, Parkinson\u2019s disease (PD), Alzheimer\u2019s disease (AD), Huntington\u2019s disease (HD) and addiction.<\/jats:p>","DOI":"10.3390\/ijms23020975","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T08:20:42Z","timestamp":1642407642000},"page":"975","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-7820","authenticated-orcid":false,"given":"Berhanu Geresu","family":"Kibret","sequence":"first","affiliation":[{"name":"Department of Biology, College of Science and Health, William Paterson University, Wayne, NJ 07470, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1620-7204","authenticated-orcid":false,"given":"Hiroki","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry and Clinical Ethics, Graduate School of Medical Science, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0597-2514","authenticated-orcid":false,"given":"Yasue","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-8927","authenticated-orcid":false,"given":"Emmanuel S.","family":"Onaivi","sequence":"additional","affiliation":[{"name":"Department of Biology, College of Science and Health, William Paterson University, Wayne, NJ 07470, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/jnc.14098","article-title":"Endocannabinoid system in neurodegenerative disorders","volume":"142","author":"Basavarajappa","year":"2017","journal-title":"J. Neurochem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2020.22.3\/vdimarzo","article-title":"The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders","volume":"22","year":"2020","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1054\/plef.2001.0341","article-title":"Cannabinoid receptors and their ligands","volume":"66","author":"Pertwee","year":"2002","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1476-5381.2010.00735.x","article-title":"The endocannabinoid system as a target for the treatment of neurodegenerative disease","volume":"160","author":"Scotter","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","article-title":"Expression of Central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations","volume":"232","author":"Mary","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0167-4781(02)00341-X","article-title":"Cloning and molecular characterization of the rat CB2 cannabinoid receptor","volume":"1576","author":"Brown","year":"2002","journal-title":"Biochim. Biophys. Acta (BBA) Gene Struct. Expr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0014-2999(99)00402-1","article-title":"Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: Further evidence for cannabinoid CB2 receptor absence in the rat central nervous system","volume":"377","author":"Griffin","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.bjp.0707567","article-title":"Targeting the cannabinoid CB2 receptor: Modelling and structural determinants of CB2 selective ligands","volume":"153","author":"Poso","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/syn.20569","article-title":"Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus","volume":"62","author":"Brusco","year":"2008","journal-title":"Synapse"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Neuroscience: Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Duncan","year":"2005","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"17410","DOI":"10.1038\/s41598-017-17796-y","article-title":"Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_13","first-page":"55","article-title":"Therapeutic potential of the cannabinoid receptor 2 in neuropsychiatry","volume":"1","author":"Navarrete","year":"2021","journal-title":"Explor. Neuroprot. Ther."},{"key":"ref_14","unstructured":"Ghose, T. (2009, June 01). The Scientist Magazine. Available online: https:\/\/www.the-scientist.com\/uncategorized\/back-on-top-44122."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1601-183X.2009.00498.x","article-title":"Species differences in cannabinoid receptor 2 (CNR2 gene): Identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands","volume":"8","author":"Liu","year":"2009","journal-title":"Genes Brain Behav."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Onaivi, E.S., Ishiguro, H., Gong, J.P., Patel, S., Meozzi, P.A., Myers, L., Perchuk, A., Mora, Z., Tagliaferro, P.A., and Gardner, E. (2008). Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: From mice to human subjects. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0001640"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1196\/annals.1432.036","article-title":"Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression","volume":"1139","author":"Onaivi","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1196\/annals.1369.052","article-title":"Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain","volume":"1074","author":"Onaivi","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/0269881111400652","article-title":"CNS effects of CB2 cannabinoid receptors: Beyond neuro-immuno-cannabinoid activity","volume":"26","author":"Onaivi","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.molmed.2012.07.009","article-title":"The endocannabinoid system in inflammatory bowel diseases: From pathophysiology to therapeutic opportunity","volume":"18","author":"Alhouayek","year":"2012","journal-title":"Trends Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/3-540-26573-2_2","article-title":"Cannabinoid receptor signaling","volume":"168","author":"Howlett","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1523\/JNEUROSCI.17-14-05327.1997","article-title":"Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a G(s) linkage to the CB1 receptor","volume":"17","author":"Glass","year":"1997","journal-title":"J. Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1677\/JME-08-0190","article-title":"Signal transduction of the CB1 cannabinoid receptor","volume":"44","author":"Turu","year":"2010","journal-title":"J. Mol. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1046\/j.1460-9568.1999.00847.x","article-title":"Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain","volume":"11","author":"Marsicano","year":"1999","journal-title":"Eur. J. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fnbeh.2011.00049","article-title":"The dopamine and cannabinoid interaction in the modulation of emotions and cognition: Assessing the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors","volume":"5","author":"Terzian","year":"2011","journal-title":"Front. Behav. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1111\/ejn.12561","article-title":"Cannabinoid receptor type 1 receptors on GABAergic vs. glutamatergic neurons differentially gate sex-dependent social interest in mice","volume":"40","author":"Terzian","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1007\/s00213-015-3917-y","article-title":"2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons","volume":"232","author":"Terzian","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jpsychires.2017.02.002","article-title":"Extinction of avoidance behavior by safety learning depends on endocannabinoid signaling in the hippocampus","volume":"90","author":"Micale","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1196\/annals.1432.037","article-title":"Ultrastructural localization of neuronal brain CB2 cannabinoid receptors","volume":"1139","author":"Brusco","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","article-title":"The endocannabinoid system and the brain","volume":"64","author":"Mechoulam","year":"2013","journal-title":"Annu. Rev. Psychol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.2174\/1568026619666190708164841","article-title":"Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development","volume":"19","author":"Nguyen","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beem.2008.09.003","article-title":"Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: Focus on anxiety and depression","volume":"23","author":"Moreira","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41401-020-00530-2","article-title":"The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders","volume":"41","author":"Xin","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0301-0082(02)00007-2","article-title":"Endocannabinoids and cannabinoid receptor genetics","volume":"66","author":"Onaivi","year":"2002","journal-title":"Prog. Neurobiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-21737-2_1","article-title":"Endocannabinoid System Components: Overview and Tissue Distribution","volume":"1162","author":"Joshi","year":"2019","journal-title":"Recent Adv. Cannabinoid Physiol. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.neubiorev.2018.12.026","article-title":"Progress in brain cannabinoid CB2 receptor research: From genes to behavior","volume":"98","author":"Jordan","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1006\/taap.1996.8034","article-title":"Cannabinoid receptors CB1 and CB2: A characterization of expression and adenylate cyclase modulation within the immune system","volume":"142","author":"Schatz","year":"1997","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_38","first-page":"1620","article-title":"Cannabinoid inhibition of the processing of intact lysozyme by macrophages: Evidence for CB2 receptor participation","volume":"289","author":"McCoy","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0014-2999(00)00211-9","article-title":"Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor","volume":"396","author":"Buckley","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainres.2005.11.035","article-title":"Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain","volume":"1071","author":"Gong","year":"2006","journal-title":"Brain Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nn.2874","article-title":"Brain cannabinoid CB2 receptors modulate cocaine\u2019s actions in mice","volume":"14","author":"Xi","year":"2011","journal-title":"Nat. Neurosci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000100778","article-title":"Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain","volume":"54","author":"Onaivi","year":"2007","journal-title":"Neuropsychobiology"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Onaivi, E.S., Ishiguro, H., and Liu, Q.R. (2015). Future perspectives: Cannabinoid CB2 receptor ligands and their therapeutic potential in mental diseases. Cannabinoids in Neurologic and Mental Disease, Academic Press.","DOI":"10.1016\/B978-0-12-417041-4.00018-7"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bjp.0707506","article-title":"Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI","volume":"153","author":"Chin","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_45","first-page":"291","article-title":"Methods to study the behavioral effects and expression of CB2 cannabinoid receptor and its gene transcripts in the chronic mild stress model of depression","volume":"123","author":"Onaivi","year":"2006","journal-title":"Methods Mol. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/aps.2016.149","article-title":"Brain cannabinoid receptor 2: Expression, function and modulation","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2010.02.013","article-title":"Functionally selective cannabinoid receptor signalling: Therapeutic implications and opportunities","volume":"80","author":"Bosier","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.3390\/ph3082517","article-title":"Brain CB2 receptors: Implications for neuropsychiatric disorders","volume":"3","author":"Roche","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"E5007","DOI":"10.1073\/pnas.1413210111","article-title":"Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00359-011-0676-z","article-title":"The role of central CB2 cannabinoid receptors on food intake in neonatal chicks","volume":"197","author":"Emadi","year":"2011","journal-title":"J. Comp. Physiol. A"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neulet.2010.12.031","article-title":"Cannabidiol decreases body weight gain in rats: Involvement of CB2 receptors","volume":"490","author":"Jankowski","year":"2011","journal-title":"Neurosci. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/0269881110379507","article-title":"Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice","volume":"25","author":"Manzanares","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Geresu, B., Canseco-Alba, A., Sanabria, B., Lin, Z., Liu, Q.R., Onaivi, E.S., and Engidawork, E. (2019). Involvement of CB2 receptors in the neurobehavioral effects of Catha edulis (Vahl) Endl. (khat) in mice. Molecules, 24.","DOI":"10.3390\/molecules24173164"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bbr.2018.11.043","article-title":"Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons","volume":"360","author":"Schanz","year":"2019","journal-title":"Behav. Brain Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/npp.2011.34","article-title":"Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice","volume":"36","author":"Navarrete","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1369\/0022155413491269","article-title":"Bilateral Changes of Cannabinoid Receptor Type 2 Protein and mRNA in the Dorsal Root Ganglia of a Rat Neuropathic Pain Model","volume":"61","year":"2013","journal-title":"J. Histochem. Cytochem."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Yu, S.J., Reiner, D., Shen, H., Wu, K.J., Liu, Q.R., and Wang, Y. (2015). Time-dependent protection of CB2 receptor agonist in stroke. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132487"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lopez-Rodriguez, A.B., Acaz-Fonseca, E., Viveros, M.P., and Garcia-Segura, L.M. (2015). Changes in cannabinoid receptors, aquaporin 4 and vimentin expression after traumatic brain injury in adolescent male mice. Association with edema and neurological deficit. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128782"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4314\/epj.v28i2.6","article-title":"Catha edulis F. (Khat) Reverses Haloperidol But Not Morphine Induced Motor Deficits Following Acute and Subacute Administration in Mice","volume":"28","author":"Geresu","year":"2012","journal-title":"Ethiop. Pharm. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.expneurol.2015.04.007","article-title":"Differential upregulation of the cannabinoid CB2 receptor in neurotoxic and inflammation-driven rat models of Parkinson\u2019s disease","volume":"269","author":"Concannon","year":"2015","journal-title":"Exp. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.drugalcdep.2013.08.023","article-title":"Differential expression and functional role of cannabinoid genes in alcohol users","volume":"133","author":"Agudelo","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1017\/S1461145712001186","article-title":"Cocaine self-administration differentially modulates the expression of endogenous cannabinoid system-related proteins in the hippocampus of Lewis vs. Fischer 344 rats","volume":"16","author":"Rivera","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/sj.tpj.6500431","article-title":"Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans","volume":"7","author":"Ishiguro","year":"2007","journal-title":"Pharmacogenom. J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1196\/annals.1432.035","article-title":"Behavioral effects of CB2 cannabinoid receptor activation and its influence on food and alcohol consumption","volume":"1139","author":"Onaivi","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"FSO625","DOI":"10.2144\/fsoa-2020-0124","article-title":"Cannabis for COVID-19: Can cannabinoids quell the cytokine storm?","volume":"6","author":"Onaivi","year":"2020","journal-title":"Futur. Sci. OA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fphar.2014.00037","article-title":"Cannabinoids for treatment of alzheimer\u2019s disease: Moving toward the clinic","volume":"5","author":"Aso","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12026-011-8210-5","article-title":"Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease","volume":"51","author":"Basu","year":"2011","journal-title":"Immunol. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.smim.2014.04.002","article-title":"What we know and do not know about the cannabinoid receptor 2 (CB2)","volume":"26","author":"Malfitano","year":"2014","journal-title":"Semin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrn4036","article-title":"The endocannabinoid system in guarding against fear, anxiety and stress","volume":"16","author":"Lutz","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2012.12.002","article-title":"Endocannabinoid system and mood disorders: Priming a target for new therapies","volume":"138","author":"Micale","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/j.1476-5381.2010.00819.x","article-title":"Depression-resistant endophenotype in mice overexpressing cannabinoid CB 2 receptors","volume":"160","author":"Manzanares","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.neuropharm.2004.12.008","article-title":"Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy","volume":"48","author":"Valenzano","year":"2005","journal-title":"Neuropharmacology"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Ishiguro, H., Horiuchi, Y., Tabata, K., Liu, Q.R., Arinami, T., and Onaivi, E.S. (2018). Cannabinoid CB2 receptor gene and environmental interaction in the development of psychiatric disorders. Molecules, 23.","DOI":"10.3390\/molecules23081836"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.b.32467","article-title":"Genetic variation in the endocannabinoid system and response to Cognitive Behavior Therapy for child anxiety disorders","volume":"174","author":"Lester","year":"2017","journal-title":"Am. J. Med. Genet. Part B Neuropsychiatr. Genet."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Micale, V., Tabiova, K., Kucerova, J., and Drago, F. (2015). Role of the endocannabinoid system in depression: From preclinical to clinical evidence. Cannabinoid Modulation of Emotion, Memory, and Motivation, Springer.","DOI":"10.1007\/978-1-4939-2294-9_5"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.pain.2009.02.018","article-title":"Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833","volume":"143","author":"Hu","year":"2009","journal-title":"Pain"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00008877-200205000-00001","article-title":"The validity of animal models of predisposition to depression","volume":"13","author":"Willner","year":"2002","journal-title":"Behav. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000087097","article-title":"Chronic mild stress (CMS) revisited: Consistency and behavioural-neurobiological concordance in the effects of CMS","volume":"52","author":"Willner","year":"2005","journal-title":"Neuropsychobiology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0014-2999(95)00697-4","article-title":"Pharmacological validation of the chronic mild stress model of depression","volume":"296","author":"Papp","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s13311-018-0610-y","article-title":"Alterations in Gene and Protein Expression of Cannabinoid CB2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims","volume":"15","author":"Navarrete","year":"2018","journal-title":"Neurotherapeutics"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jad.2020.07.074","article-title":"Regulation of cannabinoid CB1 and CB2 receptors, neuroprotective mTOR and pro-apoptotic JNK1\/2 kinases in postmortem prefrontal cortex of subjects with major depressive disorder","volume":"276","author":"Salort","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1574889809666140307115532","article-title":"Therapeutic potential of cannabinoids in schizophrenia","volume":"9","author":"Kucerova","year":"2014","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.biopsych.2003.10.024","article-title":"The effects of early maternal deprivation on auditory information processing in adult wistar rats","volume":"55","author":"Ellenbroek","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbr.2006.10.020","article-title":"Early maternal deprivation reduces prepulse inhibition and impairs spatial learning ability in adulthood: No further effect of post-pubertal chronic corticosterone treatment","volume":"176","author":"Garner","year":"2007","journal-title":"Behav. Brain Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/hipo.20537","article-title":"Early maternal deprivation induces gender-dependent changes on the expression of hippocampal CB1 and CB2 cannabinoid receptors of neonatal rats","volume":"19","author":"Llorente","year":"2009","journal-title":"Hippocampus"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"10404","DOI":"10.1523\/JNEUROSCI.1618-08.2008","article-title":"D-aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801","volume":"28","author":"Errico","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.biopsych.2009.09.024","article-title":"Brain Cannabinoid CB2 Receptor in Schizophrenia","volume":"67","author":"Ishiguro","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1007\/s00213-014-3481-x","article-title":"CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice","volume":"231","author":"Khella","year":"2014","journal-title":"Psychopharmacology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.neuropharm.2013.05.034","article-title":"Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors","volume":"73","author":"Caltana","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.neuron.2016.08.017","article-title":"Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release","volume":"91","author":"Foster","year":"2016","journal-title":"Neuron"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.neuropharm.2018.11.035","article-title":"Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia","volume":"146","author":"Stark","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"114004","DOI":"10.1016\/j.bcp.2020.114004","article-title":"Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment","volume":"177","author":"Stark","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.2174\/138161212802884681","article-title":"A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation","volume":"18","author":"Alexandre","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.phrs.2021.105938","article-title":"Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment","volume":"174","author":"Stark","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Galaj, E., and Xi, Z.X. (2021). Possible receptor mechanisms underlying cannabidiol effects on addictive-like behaviors in experimental animals. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010134"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.3389\/fphar.2020.618065","article-title":"Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders","volume":"11","author":"Scarante","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"9354","DOI":"10.1021\/acs.jmedchem.1c00561","article-title":"Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB2 Receptor Derived from the Natural Product Cannabidiol","volume":"64","author":"Navarro","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/npp.2013.165","article-title":"Peripheral endocannabinoid system dysregulation in first-episode psychosis","volume":"38","author":"Bioque","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s12031-013-0062-0","article-title":"Association of single-nucleotide polymorphisms in the cannabinoid receptor 2 gene with schizophrenia in the Han Chinese population","volume":"51","author":"Tong","year":"2013","journal-title":"J. Mol. Neurosci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bcp.2018.09.013","article-title":"Role of the endocannabinoid system in drug addiction","volume":"157","author":"Manzanares","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"S586","DOI":"10.1016\/S0924-977X(11)70959-2","article-title":"P.6.d.008 Decreased cocaine motor sensitisation and self-administration in mice overexpressing cannabinoid CB2 receptors","volume":"21","author":"Trigo","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00213-019-05370-5","article-title":"The roles of cannabinoid CB1 and CB2 receptors in cocaine-induced behavioral sensitization and conditioned place preference in mice","volume":"237","author":"Lopes","year":"2020","journal-title":"Psychopharmacology"},{"key":"ref_104","first-page":"106","article-title":"Pharmacological blockade of either cannabinoid CB1 or CB2 receptors prevents both cocaine-induced conditioned locomotion and cocaine-induced reduction of cell proliferation in the hippocampus of adult male rat","volume":"7","author":"Rivera","year":"2014","journal-title":"Front. Integr. Neurosci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"722476","DOI":"10.3389\/fphar.2021.722476","article-title":"\u03b2-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms","volume":"12","author":"He","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/adb.12076","article-title":"Role of cannabinoid CB2 receptor in the reinforcing actions of ethanol","volume":"20","author":"Ternianov","year":"2015","journal-title":"Addict. Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.pbb.2014.06.025","article-title":"The cannabinoid receptor 2 agonist, \u03b2-caryophyllene, reduced voluntary alcohol intake and attenuated ethanol-induced place preference and sensitivity in mice","volume":"124","author":"Ojha","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bbr.2015.03.051","article-title":"Interaction of cannabinoid receptor 2 and social environment modulates chronic alcohol consumption","volume":"287","author":"Pradier","year":"2015","journal-title":"Behav. Brain Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"110460","DOI":"10.1016\/j.pnpbp.2021.110460","article-title":"Acute stress and alcohol exposure during adolescence result in an anxious phenotype in adulthood: Role of altered glutamate\/endocannabinoid transmission mechanisms","volume":"113","author":"Pastor","year":"2022","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Navarrete, F., Garc\u00eda-Guti\u00e9rrez, M.S., Gasparyan, A., Navarro, D., and Manzanares, J. (2021). CB2 receptor involvement in the treatment of substance use disorders. Biomolecules, 11.","DOI":"10.3390\/biom11111556"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Do, L.L.T.N. (2011). American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Encyclopedia of Child Behavior and Development, Springer.","DOI":"10.1007\/978-0-387-79061-9_113"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s13311-015-0371-9","article-title":"Endocannabinoid Signaling in Autism","volume":"12","author":"Chakrabarti","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1007\/s10803-013-1824-9","article-title":"Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders","volume":"43","author":"Siniscalco","year":"2013","journal-title":"J. Autism Dev. Disord."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Pietropaolo, S., and Marsicano, G. (2021). The role of the endocannabinoid system as a therapeutic target for autism spectrum disorder: Lessons from behavioral studies on mouse models. Neurosci. Biobehav. Rev., in press.","DOI":"10.1016\/j.neubiorev.2021.11.031"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/MOL.0b013e32803dbdec","article-title":"Endocannabinoids and the regulation of their levels in health and disease","volume":"18","author":"Petrosino","year":"2007","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/35007534","article-title":"Central nervous system control of food intake","volume":"404","author":"Schwartz","year":"2000","journal-title":"Nature"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.npp.1300695","article-title":"Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa","volume":"30","author":"Monteleone","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.psyneuen.2008.10.014","article-title":"Elevated cannabinoid 1 receptor mRNA is linked to eating disorder related behavior and attitudes in females with eating disorders","volume":"34","author":"Frieling","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/syn.20714","article-title":"A nonsynonymous polymorphism in cannabinoid CB2 receptor gene is associated with eating disorders in humans and food intake is modified in mice by its ligands","volume":"64","author":"Ishiguro","year":"2010","journal-title":"Synapse"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s12035-016-9795-4","article-title":"Neuroprotective Effect of Fisetin Against Amyloid-Beta-Induced Cognitive\/Synaptic Dysfunction, Neuroinflammation, and Neurodegeneration in Adult Mice","volume":"54","author":"Ahmad","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3233\/JAD-180230","article-title":"Cannabinoid Receptor 2-Deficiency Ameliorates Disease Symptoms in a Mouse Model with Alzheimer\u2019s Disease-Like Pathology","volume":"64","author":"Lundt","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1016\/j.neurobiolaging.2015.08.003","article-title":"Endocannabinoid regulation of amyloid-induced neuroinflammation","volume":"36","author":"Grande","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s00018-006-6037-3","article-title":"Endocannabinoids and \u03b2-amyloid-induced neurotoxicity in vivo: Effect of pharmacological elevation of endocannabinoid levels","volume":"63","author":"Mazzola","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","article-title":"Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer\u2019s Disease Brains","volume":"23","author":"Benito","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of Alzheimer\u2019s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation","volume":"25","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.neurobiolaging.2012.06.005","article-title":"CB2 receptor and amyloid pathology in frontal cortex of Alzheimer\u2019s disease patients","volume":"34","author":"Solas","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2119\/molmed.2013.00140.revised","article-title":"CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer\u2019s disease","volume":"20","author":"Koppel","year":"2014","journal-title":"Mol. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3233\/JAD-130137","article-title":"CB2 cannabinoid receptor agonist ameliorates alzheimer-like phenotype in A\u03b2PP\/PS1 mice","volume":"35","author":"Aso","year":"2013","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_129","first-page":"422","article-title":"Vascular dysfunction in a transgenic model of Alzheimer\u2019s disease: Effects of CB1R and CB2R cannabinoid agonists","volume":"10","author":"Villalba","year":"2016","journal-title":"Front. Neurosci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.neuropharm.2016.03.015","article-title":"Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer\u2019s disease","volume":"110","author":"Lemos","year":"2016","journal-title":"Neuropharmacology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jphs.2021.08.008","article-title":"N-linoleyltyrosine exerts neuroprotective effects in APP\/PS1 transgenic mice via cannabinoid receptor-mediated autophagy","volume":"147","author":"Long","year":"2021","journal-title":"J. Pharmacol. Sci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13195-021-00920-6","article-title":"N-Methyl-D-aspartate (NMDA) and cannabinoid CB2 receptors form functional complexes in cells of the central nervous system: Insights into the therapeutic potential of neuronal and microglial NMDA receptors","volume":"13","author":"Lillo","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"134286","DOI":"10.1016\/j.neulet.2019.134286","article-title":"CB2 cannabinoid receptor agonist ameliorates novel object recognition but not spatial memory in transgenic APP\/PS1 mice","volume":"707","author":"Li","year":"2019","journal-title":"Neurosci. Lett."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neurobiolaging.2012.06.011","article-title":"Activation of the CB2 receptor system reverses amyloid-induced memory deficiency","volume":"34","author":"Wu","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2017.05.044","article-title":"Activation of CB2 receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer\u2019s disease","volume":"811","author":"Wu","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/glia.20108","article-title":"Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1\u03b2-stimulated human astrocytes","volume":"49","author":"Sheng","year":"2005","journal-title":"Glia"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1742-2094-2-29","article-title":"Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation","volume":"2","author":"Ehrhart","year":"2005","journal-title":"J. Neuroinflamm."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1523\/JNEUROSCI.23-04-01398.2003","article-title":"Nonpsychotropic cannabinoid receptors regulate microglial cell migration","volume":"23","author":"Walter","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3233\/JAD-150913","article-title":"Cannabinoid receptor 2 participates in amyloid-\u03b2 processing in a mouse model of Alzheimer\u2019s disease but plays a minor role in the therapeutic properties of a cannabis-based medicine","volume":"51","author":"Aso","year":"2016","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"5","author":"Breteler","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/jnr.21642","article-title":"Nonmotor symptoms in Parkinson\u2019s disease: Investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model","volume":"86","author":"Branchi","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","article-title":"Reactive microglia are positive for HLA-DR in the: Substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains","volume":"38","author":"McGeer","year":"1988","journal-title":"Neurology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ana.20338","article-title":"Microglial activation and dopamine terminal loss in early Parkinson\u2019s disease","volume":"57","author":"Ouchi","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","article-title":"In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease","volume":"21","author":"Gerhard","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"67837","DOI":"10.18632\/oncotarget.18871","article-title":"AM1241 alleviates MPTP-induced Parkinson\u2019s disease and promotes the regeneration of DA neurons in PD mice","volume":"8","author":"Shi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.tips.2007.02.004","article-title":"The endocannabinoid system in targeting inflammatory neurodegenerative diseases","volume":"28","author":"Centonze","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/j.1476-5381.2011.01343.x","article-title":"Endocannabinoids and traumatic brain injury","volume":"163","author":"Shohami","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1098\/rstb.2011.0381","article-title":"Targeting the endocannabinoid system with cannabinoid receptor agonists: Pharmacological strategies and therapeutic possibilities","volume":"367","author":"Pertwee","year":"2012","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.phrs.2007.09.008","article-title":"Endocannabinoids and neurodegenerative diseases","volume":"56","author":"Micale","year":"2007","journal-title":"Pharmacol. Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pnpbp.2015.03.017","article-title":"Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson\u2019s disease","volume":"64","year":"2016","journal-title":"Prog. Neuro-Psychopharmacolo. Biol. Psychiatry"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1476-5381.2011.01278.x","article-title":"Symptom-relieving and neuroprotective effects of the phytocannabinoid \u0394 9-THCV in animal models of Parkinson\u2019s disease","volume":"163","author":"Ramos","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/j.1460-9568.2009.06764.x","article-title":"WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease","volume":"29","author":"Price","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fnins.2016.00321","article-title":"Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of parkinson\u2019s disease","volume":"10","author":"Javed","year":"2016","journal-title":"Front. Neurosci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2014.12.003","article-title":"Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson\u2019s disease","volume":"587","author":"Cinquina","year":"2015","journal-title":"Neurosci. Lett."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nbd.2019.05.009","article-title":"Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor","volume":"129","author":"Eddings","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1476-5381.2008.00088.x","article-title":"The endocannabinoid system as a target for the treatment of motor dysfunction","volume":"156","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"9913","DOI":"10.1021\/acs.jmedchem.7b00155","article-title":"Perspectives of Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders: Structure-Affinity Relationship (SAfiR) and Structure-Activity Relationship (SAR) Studies","volume":"60","author":"Spinelli","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.ejmech.2017.12.097","article-title":"Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6\/2 chorea huntington mouse model and human ALS spinal cord tissue","volume":"145","author":"Haider","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/glia.20838","article-title":"Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington\u2019s disease","volume":"57","author":"Sagredo","year":"2009","journal-title":"Glia"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"18259","DOI":"10.1523\/JNEUROSCI.4008-12.2012","article-title":"Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington\u2019s disease","volume":"32","author":"Bouchard","year":"2012","journal-title":"J. Neurosci."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"44","DOI":"10.21037\/sci.2019.10.06","article-title":"Safety and efficacy of stem cell therapy for treatment of neural damage in patients with multiple sclerosis","volume":"6","author":"Bejargafshe","year":"2019","journal-title":"Stem Cell Investig."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.drudis.2019.05.023","article-title":"Cannabinoid receptors as therapeutic targets for autoimmune diseases: Where do we stand?","volume":"24","author":"Dutra","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1471-4159.2005.03380.x","article-title":"Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli","volume":"95","author":"Maresz","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"13320","DOI":"10.1074\/jbc.M707960200","article-title":"The CB2 cannabinoid receptor controls myeloid progenitor trafficking: Involvement in the pathogenesis of an animal model of multiple sclerosis","volume":"283","author":"Palazuelos","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11481-009-9148-4","article-title":"Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke","volume":"4","author":"Zhang","year":"2009","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Alberti, T.B., Barbosa, W.L.R., Vieira, J.L.F., Raposo, N.R.B., and Dutra, R.C. (2017). (\u2212)-\u03b2-caryophyllene, a CB2 receptor-selective phytocannabinoid, suppresses motor paralysis and neuroinflammation in a murine model of multiple sclerosis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18040691"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1460-9568.2008.06377.x","article-title":"Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide","volume":"28","author":"Petrosino","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1523\/JNEUROSCI.23-07-02511.2003","article-title":"Therapeutic action of cannabinoids in a murine model of multiple sclerosis","volume":"23","author":"Vela","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuropharm.2012.04.012","article-title":"A CB 1\/CB 2 receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin","volume":"63","author":"Guaza","year":"2012","journal-title":"Neuropharmacology"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12031-019-01395-9","article-title":"Cannabinoid CB2 Receptor Functional Variation (Q63R) Is Associated with Multiple Sclerosis in Iranian Subjects","volume":"70","author":"Tahamtan","year":"2020","journal-title":"J. Mol. Neurosci."},{"key":"ref_172","first-page":"119","article-title":"Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-\u03b2: A longitudinal study in multiple sclerosis patients","volume":"179","author":"Giuffrida","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Yiangou, Y., Facer, P., Durrenberger, P., Chessell, I.P., Naylor, A., Bountra, C., Banati, R.R., and Anand, P. (2006). COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol., 6.","DOI":"10.1186\/1471-2377-6-12"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1523\/JNEUROSCI.4814-06.2007","article-title":"Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis","volume":"27","author":"Benito","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s004150050552","article-title":"The role of excitotoxicity in ALS what is the evidence?","volume":"247","author":"Ludolph","year":"2000","journal-title":"J. Neurol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1471-4159.2006.04346.x","article-title":"The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset","volume":"101","author":"Shoemaker","year":"2007","journal-title":"J. Neurochem."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejphar.2006.05.025","article-title":"AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis","volume":"542","author":"Kim","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/bph.14216","article-title":"Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis","volume":"176","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11481-015-9602-4","article-title":"Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: Relevance for a neuroprotective therapy in TDP-43-related disorders","volume":"10","author":"Piscitelli","year":"2015","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/cns.12262","article-title":"Changes in endocannabinoid receptors and enzymes in the spinal cord of sod1g93a transgenic mice and evaluation of a sativex\u00ae-like combination of phytocannabinoids: Interest for future therapies in amyotrophic lateral sclerosis","volume":"20","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Ji, X., Zeng, Y., and Wu, J. (2021). The CB2 receptor as a novel therapeutic target for epilepsy treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168961"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.intimp.2019.04.028","article-title":"Neuroprotective effects of isoliquiritigenin against cognitive impairment via suppression of synaptic dysfunction, neuronal injury, and neuroinflammation in rats with kainic acid-induced seizures","volume":"72","author":"Zhu","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.celrep.2016.06.083","article-title":"Crucial Roles of the Endocannabinoid 2-Arachidonoylglycerol in the Suppression of Epileptic Seizures","volume":"16","author":"Sugaya","year":"2016","journal-title":"Cell Rep."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of Cannabidiol on Drop Seizures in the Lennox\u2013Gastaut Syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/epi.16542","article-title":"Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials","volume":"61","author":"Bialer","year":"2020","journal-title":"Epilepsia"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41401-019-0210-3","article-title":"Cannabis, cannabinoid receptors, and endocannabinoid system: Yesterday, today, and tomorrow","volume":"40","author":"Wu","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eplepsyres.2015.08.010","article-title":"Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors","volume":"117","author":"Aghaei","year":"2015","journal-title":"Epilepsy Res."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/1874467213666200510004622","article-title":"Anticonvulsant, Anxiolytic and Antidepressant Properties of the \u03b2-caryophyllene in Swiss Mice: Involvement of Benzodiazepine-GABAAergic, Serotonergic and Nitrergic Systems","volume":"14","author":"Feitosa","year":"2020","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/epi.13842","article-title":"Anticonvulsant effect of cannabinoid receptor agonists in models of seizures in developing rats","volume":"58","author":"Huizenga","year":"2017","journal-title":"Epilepsia"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eplepsyres.2016.08.011","article-title":"The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats","volume":"127","author":"Hoeller","year":"2016","journal-title":"Epilepsy Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/epi.16388","article-title":"Reduced cannabinoid 2 receptor activity increases susceptibility to induced seizures in mice","volume":"60","author":"Shapiro","year":"2019","journal-title":"Epilepsia"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12975-011-0125-x","article-title":"Blood-Brain Barrier Pathophysiology in Traumatic Brain Injury","volume":"2","author":"Chodobski","year":"2011","journal-title":"Transl. Stroke Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jnr.23114","article-title":"A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury","volume":"90","author":"Amenta","year":"2012","journal-title":"J. Neurosci. Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1089\/neu.2010.1672","article-title":"Acute effects of a selective cannabinoid-2 receptor agonist on neuroinflammation in a model of traumatic brain injury","volume":"28","author":"Elliott","year":"2011","journal-title":"J. Neurotrauma"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1089\/neu.2018.6063","article-title":"Role of CB2 Receptor in the Recovery of Mice after Traumatic Brain Injury","volume":"36","author":"Magid","year":"2019","journal-title":"J. Neurotrauma"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"113899","DOI":"10.1016\/j.expneurol.2021.113899","article-title":"Selective activation of cannabinoid receptor-2 reduces white matter injury via PERK signaling in a rat model of traumatic brain injury","volume":"347","author":"Li","year":"2022","journal-title":"Exp. Neurol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cell.2018.12.011","article-title":"Crystal Structure of the Human Cannabinoid Receptor CB2","volume":"176","author":"Li","year":"2019","journal-title":"Cell"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/2\/975\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:02:16Z","timestamp":1760133736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/2\/975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":198,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["ijms23020975"],"URL":"https:\/\/doi.org\/10.3390\/ijms23020975","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]}}}